New Team Science Award is $1.5 million Over Three Years NEW YORK, June 17, 2025 /PRNewswire/ -- The Lung Cancer Research Foundation (LCRF) announces today a new funding mechanism: the 2025 LCRF Team ...

Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, Medicare patients.

Pivotal results from the Phase 3 BREAKWATER trial showed 51% risk reduction in death compared to standard-of-care treatment BRAFTOVI combination regimen also demonstrated 47% risk reduction in ...

C4 Therapeutics is sawing off another part of its solely owned pipeline, this time ending work on its clinical-stage BRAF degrader program in order to focus on its IKZF1/3 degrader cemsidomide.

BRAF will begin moving next month into the lower level of the office building at the corner of Florida and 4th streets, where Chase bank once operated a branch. It will take about four months to ...

BRAF-positive non-small cell lung cancer (NSCLC) treatments can use the BRAF biomarker to provide effective, targeted treatment for this subset of lung cancer. BRAF-positive NSCLC is an uncommon ...

Combination of dual-targeted therapies and chemotherapy shows high response rates in BRAF-mutated metastatic colorectal cancer Phase III trial results supported recent FDA approval for patients ...

NEW YORK, Sept 14 (Reuters) - Pfizer (PFE.N), opens new tab is trying to increase doctor awareness of and testing for a rare lung cancer mutation to help boost use of its drug Braftovi, which the ...

Ojemda is the first FDA-approved systemic therapy for pediatric LGG patients with BRAF rearrangements, including fusions. The Food and Drug Administration (FDA) has granted accelerated approval to ...

Pfizer's Braftovi will take the lead, boasting $424 million in sales Since Roche’s Zelboraf gained FDA approval in 2011, significant strides have been made in BRAF-targeted cancer therapies ...

The results continue to demonstrate promising single-agent activity against BRAF V600-mutated tumors, including primary central nervous system tumors (PCNSTs), as presented at the Society for ...

Following the recent FDA approval of Braftovi with Mektovi for some patients with NSCLC and a BRAF V600E mutation, a lung cancer expert explains the science behind the news. The recent approval by the ...